Treatment with VP-16 and the combination of VP-16 with IFN upregulated TRAIL expression in the bone marrow mononuclear cells of patients with acute leukemia at 24 h after the treatment, as compared with that in the control group (p<0.05). This evidence concerns the gene TNFSF10 and acute leukemia.